Molecular engineering of complementary glucose-responsive conformational switches in insulin and glucagon
胰岛素和胰高血糖素中互补葡萄糖响应构象开关的分子工程
基本信息
- 批准号:10263301
- 负责人:
- 金额:$ 58.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAffinityAlgorithmsAnimal TestingAnimalsAttenuatedB-LymphocytesBindingBiological AssayBiophysicsBloodBlood GlucoseBoronBoronic AcidsCarbohydratesCell Culture TechniquesCell physiologyChemistryClinicalClinical EndocrinologyClinical ManagementClosure by clampComplexComputer SimulationComputersCryoelectron MicroscopyCrystallizationDataDependenceDevelopmentDevicesDiabetes MellitusDoseElementsEndocrinologyEngineeringExclusionFemaleFormulationFoundationsGlucagonGlucagon ReceptorGlucoseGlycolsGoalsHealthHeteronuclear NMRHomeostasisHormonalHormone ReceptorHormone replacement therapyHormonesHyperglycemiaHypoglycemiaInjectionsInsulinInsulin Infusion SystemsInsulin ReceptorInsulin, Lispro, HumanInsulin-Dependent Diabetes MellitusJointsLeadLigandsMeasuresMetabolicMetabolismMethodsModelingMolecularMolecular ConformationNatureNon-Insulin-Dependent Diabetes MellitusOutcomePatientsPeptidesPerformancePharmacologyPhysiologyPlayPositioning AttributePropertyProtein EngineeringProto-Oncogene Proteins c-aktPublicationsPumpRat-1RattusReceptor SignalingRecommendationResearch PersonnelRestRiskRoleSafetySchemeSeriesSomatostatinSpecificityStreamStreptozocinStructureSynthesis ChemistrySystemTechnologyTimeVariantWeight GainWestern BlottingX-Ray CrystallographyYanganalogbaseclinical candidatedesigndiabetic ratfrontierhormone analogimage reconstructionin silicoin vivoinnovationinterdisciplinary approachmalemathematical modelmultidisciplinarynext generationnoveloperationparticlepatient subsetsphosphoproteomicsprototypesimulationstructural biologysugarthree dimensional structure
项目摘要
Project Summary
Insulin and glucagon play central roles in metabolic homeostasis with long-standing application to the clinical
management of diabetes mellitus (DM). This MPI application focuses on the development of glucose-responsive
analogs of these hormones. The proposed technology promises to enhance the safety and efficacy of hormone
replacement therapy, including in innovative bihormonal pumps in closed-loop systems. This is a key frontier of
molecular pharmacology and non-standard protein engineering.
The multidisciplinary MPI team encompasses protein design, biophysics, structural biology, animal physiology,
clinical endocrinology, and computer simulations of mammalian metabolism. Animal studies will be performed in
normal and STZ rats under the guidance of Prof. F. Ismail-Beigi (Subcontract to CWRU); computer-based
interpretation of these studies as part of a design cycle will be undertaken in simulated models by Prof. M. Strano
and coworkers (Subcontract to MIT). Cryo-EM studies of variant insulin-insulin receptor (IR) complexes will be
performed by Prof. M.C. Lawrence (Subcontract to WEHI, Melbourne AU). The MPI team has recent joint
publications, including in Nature Chemistry, J. Biol. Chem. and Diabetes.
Glucose-responsive insulin (GRI) analogs are envisioned as a technology to attenuate IR signaling under
conditions of hypoglycemia; glucose-responsive glucagon (GRG) analogs are envisioned as a complementary
technology to attenuate glucagon-receptor (GlR) signaling under conditions of hyperglycemia. Respective
protein design rests upon two complementary premises:
Hypothesis 1: That development of an appropriate glucose-binding element (GBE) will enable
construction of a glucose-regulated conformational switch between a glucose-free closed (inactive) state
and a glucose-bound open (active) state in accord with how WT insulin binds to and activates the IR; and
Hypothesis 2: That development of a distinct GBE will enable construction of a glucose-regulated
conformational switch between a glucose-bound inactive state and a glucose-free active state in
accordance with how WT glucagon binds to and activates the GlR.
In each case the GBEs will exploit the diol-binding properties boronic acids and benzoxaboroles. Binding of
glucose in a GRI activates the hormone whereas binding of glucose in a GRG inactivates the hormone. Aims 1-
3 focus on GRIs whereas Aim 4 extends our approach to GRGs. These technologies may markedly enhance
the long-term health of patients with T1D and a subset of patients with T2D.
Protein design will be based on classical crystal structures of insulin and glucagon, extended by dramatic recent
advances in the structural biology of the IR, GlR and their respective ligand complexes. Salient structural
differences between these systems promise to enable construction of opposing switches. An interdisciplinary
team Approach is proposed within integrated MPI Management Plan.
项目摘要
胰岛素和胰高血糖素长期应用于临床,在代谢动态平衡中发挥重要作用
管理糖尿病(DM)。这个MPI应用程序专注于开发葡萄糖响应型
这些激素的类似物。这项拟议的技术有望提高激素的安全性和有效性。
替代疗法,包括在闭环系统中的创新双激素泵。这是一个关键的前沿领域
分子药理学和非标准蛋白质工程。
多学科MPI团队涵盖蛋白质设计、生物物理学、结构生物学、动物生理学、
临床内分泌学和哺乳动物新陈代谢的计算机模拟。动物研究将在
正常和STZ大鼠在F·伊斯梅尔-贝吉教授(转包给CWRU)的指导下;计算机辅助
作为设计周期的一部分,M·斯特拉诺教授将在模拟模型中对这些研究进行解释
和同事(转包给麻省理工学院)。各种胰岛素-胰岛素受体(IR)复合体的冷冻-EM研究将
由M.C.劳伦斯教授执行(转包给澳大利亚墨尔本WEHI)。MPI团队最近联合
出版,包括《自然化学》,J.Biol。化学。和糖尿病。
葡萄糖反应胰岛素(GRI)类似物被认为是一种在
低血糖状态;葡萄糖反应高血糖素(GRG)类似物被认为是一种补充
在高血糖条件下减弱胰升糖素受体(GLR)信号的技术。各自
蛋白质设计基于两个互补的前提:
假设1:适当的葡萄糖结合元件(GBE)的发展将使
无糖封闭(非活性)状态间葡萄糖调控构象开关的构建
和葡萄糖结合的开放(活性)状态,符合WT胰岛素与IR结合和激活的方式;以及
假设2:不同的GBE的发展将使葡萄糖调节的
在葡萄糖结合的非活性状态和无葡萄糖活性状态之间的构象转换
根据WT胰高血糖素与GLR结合和激活的方式。
在每一种情况下,GBE都将利用二元醇的结合特性,即硼酸和苯并氧硼化合物。约束:
GRI中的葡萄糖激活荷尔蒙,而GRG中葡萄糖的结合则使激素失活。AIMS 1-
3侧重于GRI,而AIM 4则将我们的方法扩展到GRG。这些技术可能会显著增强
T1D患者和部分T2D患者的长期健康状况。
蛋白质设计将基于胰岛素和胰高血糖素的经典晶体结构,并在最近戏剧性地扩展
IR、GLR及其配体络合物的结构生物学研究进展突出的结构
这些系统之间的差异有望实现相反的交换机的构建。跨学科的
团队方法在综合MPI管理计划中提出。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FARAMARZ ISMAIL-BEIGI其他文献
FARAMARZ ISMAIL-BEIGI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FARAMARZ ISMAIL-BEIGI', 18)}}的其他基金
Molecular endocrinology and principles of diabetes therapeutics: application to ultra-stable insulin analogs
分子内分泌学和糖尿病治疗原理:超稳定胰岛素类似物的应用
- 批准号:
10155480 - 财政年份:2020
- 资助金额:
$ 58.36万 - 项目类别:
Molecular engineering of complementary glucose-responsive conformational switches in insulin and glucagon
胰岛素和胰高血糖素中互补葡萄糖响应构象开关的分子工程
- 批准号:
10443890 - 财政年份:2020
- 资助金额:
$ 58.36万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 58.36万 - 项目类别:
Continuing Grant